Literature DB >> 11992141

A critical review on Chagas disease chemotherapy.

José Rodriques Coura1, Solange L de Castro.   

Abstract

In this "Critical Review" we made a historical introduction of drugs assayed against Chagas disease beginning in 1912 with the works of Mayer and Rocha Lima up to the experimental use of nitrofurazone. In the beginning of the 70s, nifurtimox and benznidazole were introduced for clinical treatment, but results showed a great variability and there is still a controversy about their use for chronic cases. After the introduction of these nitroheterocycles only a few compounds were assayed in chagasic patients. The great advances in vector control in the South Cone countries, and the demonstration of parasite in chronic patients indicated the urgency to discuss the etiologic treatment during this phase, reinforcing the need to find drugs with more efficacy and less toxicity. We also review potential targets in the parasite and present a survey about new classes of synthetic and natural compounds studied after 1992/1993, with which we intend to give to the reader a general view about experimental studies in the area of the chemotherapy of Chagas disease, complementing the previous papers of Brener (1979) and De Castro (1993).

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11992141     DOI: 10.1590/s0074-02762002000100001

Source DB:  PubMed          Journal:  Mem Inst Oswaldo Cruz        ISSN: 0074-0276            Impact factor:   2.743


  203 in total

1.  Arylimidamide DB766, a potential chemotherapeutic candidate for Chagas' disease treatment.

Authors:  Denise da Gama Jaén Batista; Marcos Meuser Batista; Gabriel Melo de Oliveira; Patrícia Borges do Amaral; Joseli Lannes-Vieira; Constança Carvalho Britto; Angela Junqueira; Marli Maria Lima; Alvaro José Romanha; Policarpo Ademar Sales Junior; Chad E Stephens; David W Boykin; Maria de Nazaré Correia Soeiro
Journal:  Antimicrob Agents Chemother       Date:  2010-05-10       Impact factor: 5.191

2.  Use of the Trypanosoma cruzi recombinant complement regulatory protein to evaluate therapeutic efficacy following treatment of chronic chagasic patients.

Authors:  Wendell S F Meira; Lúcia M C Galvão; Eliane D Gontijo; George L L Machado-Coelho; Karen A Norris; Egler Chiari
Journal:  J Clin Microbiol       Date:  2004-02       Impact factor: 5.948

3.  3D QSAR studies on binding affinities of coumarin natural products for glycosomal GAPDH of Trypanosoma cruzi.

Authors:  Irwin R A Menezes; Julio C D Lopes; Carlos A Montanari; Glaucius Oliva; Fernando Pavão; Marcelo S Castilho; Paulo C Vieira; Mônica T Pupo
Journal:  J Comput Aided Mol Des       Date:  2003 May-Jun       Impact factor: 3.686

4.  In vitro and in vivo trypanocidal synergistic activity of N-butyl-1-(4-dimethylamino)phenyl-1,2,3,4-tetrahydro-β-carboline-3-carboxamide associated with benznidazole.

Authors:  Rodrigo Hinojosa Valdez; Lilian Tatiani Düsman Tonin; Tânia Ueda-Nakamura; Sueli Oliveira Silva; Benedito Prado Dias Filho; Edilson Nobuyoshi Kaneshima; Sueli Fumie Yamada-Ogatta; Lucy Megumi Yamauchi; Maria Helena Sarragiotto; Celso Vataru Nakamura
Journal:  Antimicrob Agents Chemother       Date:  2011-10-28       Impact factor: 5.191

Review 5.  Cardiac involvement with parasitic infections.

Authors:  Alicia Hidron; Nicholas Vogenthaler; José I Santos-Preciado; Alfonso J Rodriguez-Morales; Carlos Franco-Paredes; Anis Rassi
Journal:  Clin Microbiol Rev       Date:  2010-04       Impact factor: 26.132

6.  Amiodarone inhibits Trypanosoma cruzi infection and promotes cardiac cell recovery with gap junction and cytoskeleton reassembly in vitro.

Authors:  Daniel Adesse; Eduardo Meirelles Azzam; Maria de Nazareth L Meirelles; Julio A Urbina; Luciana R Garzoni
Journal:  Antimicrob Agents Chemother       Date:  2010-11-15       Impact factor: 5.191

7.  Comparative efficacies of TAK-187, a long-lasting ergosterol biosynthesis inhibitor, and benznidazole in preventing cardiac damage in a murine model of Chagas' disease.

Authors:  Milagros Corrales; Rubén Cardozo; María Asunción Segura; Julio A Urbina; Miguel Angel Basombrío
Journal:  Antimicrob Agents Chemother       Date:  2005-04       Impact factor: 5.191

8.  Deletion of the Trypanosoma brucei superoxide dismutase gene sodb1 increases sensitivity to nifurtimox and benznidazole.

Authors:  S Radhika Prathalingham; Shane R Wilkinson; David Horn; John M Kelly
Journal:  Antimicrob Agents Chemother       Date:  2006-12-04       Impact factor: 5.191

9.  Artemisinins inhibit Trypanosoma cruzi and Trypanosoma brucei rhodesiense in vitro growth.

Authors:  Yuliya V Mishina; Sanjeev Krishna; Richard K Haynes; John C Meade
Journal:  Antimicrob Agents Chemother       Date:  2007-03-05       Impact factor: 5.191

10.  Trypanosoma cruzi infection and benznidazole therapy independently stimulate oxidative status and structural pathological remodeling of the liver tissue in mice.

Authors:  Rômulo Dias Novaes; Eliziária C Santos; Marli C Cupertino; Daniel S S Bastos; Jerusa M Oliveira; Thaís V Carvalho; Mariana M Neves; Leandro L Oliveira; André Talvani
Journal:  Parasitol Res       Date:  2015-04-28       Impact factor: 2.289

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.